Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial
- 26 March 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Rheumatology
- Vol. 2 (5), e260-e269
- https://doi.org/10.1016/s2665-9913(20)30057-6
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Sjögren's SyndromeAnnual Review Of Pathology-Mechanisms Of Disease, 2014
- EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trialAnnals Of The Rheumatic Diseases, 2013
- Advances in understanding the pathogenesis of primary Sjögren's syndromeNature Reviews Rheumatology, 2013
- New insights into mechanisms of therapeutic effects of antimalarial agents in SLENature Reviews Rheumatology, 2012
- Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2011
- Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot studyAnnals Of The Rheumatic Diseases, 2007
- Activation of the type I interferon system in primary Sjögren's syndrome: A possible etiopathogenic mechanismArthritis & Rheumatism, 2005
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptorsNature, 2002
- Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial.Annals Of The Rheumatic Diseases, 1993